- Home
- NBB vs ALMS Comparison
NBB vs ALMS Comparison
Compare NBB & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBB
- ALMS
- Stock Information
- Founded
- NBB 2009
- ALMS 2021
- Country
- NBB United States
- ALMS United States
- Employees
- NBB N/A
- ALMS N/A
- Industry
- NBB Finance Companies
- ALMS
- Sector
- NBB Finance
- ALMS
- Exchange
- NBB Nasdaq
- ALMS NYSE
- Market Cap
- NBB 462.1M
- ALMS 402.6M
- IPO Year
- NBB N/A
- ALMS 2024
- Fundamental
- Price
- NBB $15.66
- ALMS $3.52
- Analyst Decision
- NBB
- ALMS Strong Buy
- Analyst Count
- NBB 0
- ALMS 7
- Target Price
- NBB N/A
- ALMS $24.50
- AVG Volume (30 Days)
- NBB 73.9K
- ALMS 841.5K
- Earning Date
- NBB 01-01-0001
- ALMS 08-12-2025
- Dividend Yield
- NBB 8.64%
- ALMS N/A
- EPS Growth
- NBB N/A
- ALMS N/A
- EPS
- NBB N/A
- ALMS N/A
- Revenue
- NBB N/A
- ALMS $17,389,000.00
- Revenue This Year
- NBB N/A
- ALMS N/A
- Revenue Next Year
- NBB N/A
- ALMS N/A
- P/E Ratio
- NBB N/A
- ALMS N/A
- Revenue Growth
- NBB N/A
- ALMS N/A
- 52 Week Low
- NBB $13.67
- ALMS $2.76
- 52 Week High
- NBB $16.66
- ALMS $13.50
- Technical
- Relative Strength Index (RSI)
- NBB 50.83
- ALMS N/A
- Support Level
- NBB $15.62
- ALMS N/A
- Resistance Level
- NBB $15.91
- ALMS N/A
- Average True Range (ATR)
- NBB 0.20
- ALMS 0.00
- MACD
- NBB -0.00
- ALMS 0.00
- Stochastic Oscillator
- NBB 55.36
- ALMS 0.00
About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests primarily in a diversified portfolio of taxable municipal securities.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.